Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > TRVI Trevi Therapeutics > Company Executives
TRVI Trevi Therapeutics
NamePositionSalaryService DateEducationAgeGenderUpdated
Ms. Jennifer L. GoodPresident, Chief Executive Officer and Director1.53M----57female04/29/2022
Dr. William P. ForbesChief Development Officer1.18M----60male04/29/2022
Dr. Thomas R. Sciascia,M.D.Chief Medical Officer717.54K----68male04/29/2022
Ms. Lisa DelfiniChief Financial Officer------52female04/29/2022
Mr. Christopher GallettaTreasurer, Controller and Principal Accounting Officer--------male03/17/2022
Dr. David P. Meeker,M.D.Chairman of the Board102.77K----67male04/29/2022
Ms. Anne M. VanlentIndependent Director91.77K----74female04/29/2022
Mr. Dominick C. ColangeloIndependent Director85.27K----58male04/29/2022
Mr. Edward T. MathersIndependent Director77.77K----62male04/29/2022
Dr. James V. Cassella,PhDIndependent Director76.77K----67male04/29/2022
Mr. Michael T. HeffernanLead Independent Director90.27K----57male04/29/2022
Company Overview More
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
CEO: Good, Jennifer L.
Market: NASDAQ
Futu Hot List
SymbolLatest price%Chg


Back to the Top